Barclays PLC Alaunos Therapeutics, Inc. Transaction History

Barclays PLC

  • $327 Billion
  • Q2 2024

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 03, 2022
BUY
$1.04 - $322.5 $141,581 - $43.9 Million
136,136 New
136,136 $234,000
Q2 2022

Aug 12, 2022
SELL
$0.41 - $1.24 $14,361 - $43,433
-35,027 Closed
0 $0
Q1 2022

May 16, 2022
SELL
$0.62 - $1.17 $136,032 - $256,706
-219,407 Reduced 86.23%
35,027 $24,000
Q4 2021

Feb 14, 2022
BUY
$1.09 - $1.89 $182,717 - $316,822
167,631 Added 193.12%
254,434 $278,000
Q3 2021

Nov 09, 2021
BUY
$1.44 - $2.73 $81,717 - $154,922
56,748 Added 188.81%
86,803 $158,000
Q2 2021

Aug 13, 2021
SELL
$2.63 - $3.67 $395,888 - $552,437
-150,528 Reduced 83.36%
30,055 $80,000
Q1 2021

May 13, 2021
BUY
$2.82 - $5.6 $307,552 - $610,741
109,061 Added 152.49%
180,583 $650,000
Q4 2020

Feb 11, 2021
SELL
$2.09 - $3.09 $54,266 - $80,231
-25,965 Reduced 26.63%
71,522 $180,000
Q3 2020

Nov 12, 2020
SELL
$2.39 - $3.43 $53,285 - $76,471
-22,295 Reduced 18.61%
97,487 $245,000
Q2 2020

Aug 12, 2020
BUY
$2.2 - $3.71 $121,028 - $204,098
55,013 Added 84.94%
119,782 $393,000
Q1 2020

May 13, 2020
SELL
$1.9 - $4.98 $238,594 - $625,368
-125,576 Reduced 65.97%
64,769 $158,000
Q4 2019

Feb 10, 2020
BUY
$3.95 - $5.35 $59,810 - $81,009
15,142 Added 8.64%
190,345 $898,000
Q3 2019

Nov 14, 2019
SELL
$4.13 - $6.94 $460,565 - $773,927
-111,517 Reduced 38.89%
175,203 $751,000
Q2 2019

Aug 14, 2019
BUY
$3.98 - $6.2 $404,336 - $629,870
101,592 Added 54.88%
286,720 $1.67 Million
Q1 2019

May 15, 2019
BUY
$2.0 - $4.4 $207,132 - $455,690
103,566 Added 126.98%
185,128 $713,000
Q4 2018

Feb 14, 2019
SELL
$1.61 - $3.62 $98,895 - $222,362
-61,426 Reduced 42.96%
81,562 $152,000
Q3 2018

Nov 14, 2018
BUY
$2.26 - $3.27 $243,894 - $352,891
107,918 Added 307.72%
142,988 $457,000
Q2 2018

Aug 14, 2018
BUY
$3.02 - $4.94 $23,574 - $38,561
7,806 Added 28.63%
35,070 $106,000
Q1 2018

May 15, 2018
SELL
$3.46 - $5.14 $185,691 - $275,853
-53,668 Reduced 66.31%
27,264 $106,000
Q4 2017

Feb 14, 2018
BUY
$4.0 - $6.54 $86,584 - $141,564
21,646 Added 36.51%
80,932 $335,000
Q3 2017

Nov 14, 2017
BUY
$4.99 - $6.57 $295,837 - $389,509
59,286
59,286 $364,000

Others Institutions Holding TCRT

# of Institutions
5
Shares Held
92.6K
Call Options Held
0
Put Options Held
0
View Full List

About Alaunos Therapeutics, Inc.

TCRT Quotes by TradingView
  • Ticker TCRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,182,000
  • Market Cap $443M
  • Description
  • Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...
More about TCRT
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email